Stifel raised the firm’s price target on Align Technology to $400 from $350 and keeps a Buy rating on the shares. Respondents to the firm’s survey point to “solid” 2024 year-over-year case volume growth and while Invisalign’s share is expected to step down “modestly” year-over-year, new product feedback is upbeat, says the firm, which adds that it has “an upside bias to our 2024 revenue estimate.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGN:
- Align Technology launches integrated consumer campaign
- Align Technology price target raised to $350 from $340 at Stifel
- Early notable gainers among liquid option names on March 13th
- Align Technology price target raised to $355 from $335 at Piper Sandler
- Moderna downgraded, Gap upgraded: Wall Street’s top analyst calls